Drugmakers Defend No-Cash Patent Deals Post-Actavis
Drugmakers are scrambling to limit the scope of the U.S. Supreme Court's landmark antitrust decision in Federal Trade Commission v. Actavis, arguing with mixed results that the ruling only requires extra...To view the full article, register now.
Already a subscriber? Click here to view full article